[Is the same tyrosine kinase inhibitor still effective after development of brain metastases? A Case report]

Area of Science:

• Oncology
• Medical Science

Background:

• Renal cell cancer (RCC) treatment has advanced with targeted therapies like tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors.
• Brain metastases in RCC patients present a significant therapeutic challenge, especially when there is no concurrent progression elsewhere.

Observation:

• This case report focuses on a patient with renal cell cancer who developed brain metastases while on targeted therapy.
• The patient received local whole brain irradiation concurrently with their ongoing targeted therapy.

Findings:

• Continuing the same targeted therapy (TKIs or mTOR inhibitors) after whole brain irradiation for brain metastases is a viable strategy.
• This approach led to meaningful overall survival in the patient, despite the development of central nervous system disease.

Implications:

• This suggests that targeted therapies can be safely continued in combination with radiation for brain metastases in RCC.
• This finding may help resolve the treatment dilemma for a specific subgroup of RCC patients with brain metastases, potentially improving outcomes and quality of life.